Cynosure, the Cutera-owned aesthetic device subsidiary, has launched XERF, a next-generation monopolar RF platform, in European markets. The platform targets the growing demand for non-invasive skin tightening, positioning itself as a clinical and commercial alternative to existing monopolar RF systems like InMode's Morpheus8 and Lumenis' Thermage.
Devices & Tech
Cynosure Launches XERF Monopolar RF Platform in Europe — Next-Gen Skin Tightening Enters Market
Cutera's subsidiary rolls out next-generation monopolar RF technology targeting non-invasive skin tightening demand across the continent.
1-YEAR MOVE
INMD▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Next-generation monopolar RF enters Europe as skin-tightening demand accelerates.
Monopolar RF remains a high-margin procedure category for medspa owners—typically $2,000–$4,000 per treatment with minimal consumables. XERF's European entry signals Cynosure's intent to recapture market share in a segment where InMode has gained ground over the past three years. Practices currently using competing platforms should evaluate XERF's treatment parameters, handpiece ergonomics, and rebate/financing terms. The regulatory pathway in Europe is typically faster than FDA 510(k) review in the US, so North American availability may follow within 12–18 months.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.